RegeneRx Biopharmaceuticals, Inc. has announced that Thymosin beta 4 (TB4), administered to rats after embolic stroke, improved neurological functional outcome compared to control animals. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System. Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant.

Read the full story here